B-cell activity of polyclonal antithymocyte globulins

Transplantation

Volumn 82, Issue 11, 2006, Pages 1387-1395

  Zand, Martin S ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Alloantibodies; Apoptosis; B cell; Plasma cell; Polyclonal antilymphocyte serum

Indexed keywords

CD20 ANTIBODY; CD30 ANTIBODY; CD30 ANTIGEN; CD32 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; FAS ANTIGEN; GLOBULIN; HLA DR ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 6 RECEPTOR; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RITUXIMAB; STEROID; SYNDECAN 1; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY;

ANTIBODY MEDIATED REJECTION; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW; CELL ACTIVITY; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; MYELOMA; NONHUMAN; ORGAN TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; THYMUS;

ANIMALS; ANTIGENS, CD20; ANTILYMPHOCYTE SERUM; B-LYMPHOCYTES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; RABBITS; SYNDECAN-1; THYMUS GLAND;

EID: 33845687340     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000244063.05338.27     Document Type: Review

References (120)

1. Monaco AP, Wood ML, Russell PS. Some effects of purified heterologous antihuman lymphocyte serum in man. Transplantation 1967; 5(4 Suppl): 1106.
2. Starzl TE, Marchioro TL, Hutchinson DE, et al. The clinical use of antilymphocyte globulin in renal homotransplantation. Transplantation 1967; 5(4 Suppl): 1100.
3. Najarian JS, Merkel FK, Simmons RL, Moore GE. Studies of antilymphoblast globulin in clinical organ transplantation. Br J Surg 1969; 56(8): 616.
4. Starzl TE, Brettschneider L, Penn I, et al. A trial with heterologous antilymphocyte globulin in man. Transplant Proc 1969; 1(1): 448.
5. Najarian JS, Merkel FK, Moore GE, et al. Clinical use of antilymphoblast serum. Transplant Proc 1969; 1(1): 460.
6. Jooste SV. Immunologic effects of heterologous antilymphocytic sera. Lymphology 1970; 3(2): 79.
7. Govallo VI, Kosmiadi GA. Effects of heterologous antilymphocyte and antithymocyte sera in rabbit skin allotransplantation. Folia Biol (Praha) 1968; 14(4): 293.
8. Braf ZF, Smellie WA, Williams GM, Hume DM. Evaluation of antithymocyte serum in the treatment of canine renal homografts. Surg Gynecol Obstet 1969; 129(1): 71.
9. Simmons RL, Condie R, Najarian JS. Antilymphoblast globulin for renal allograft prolongation. Transplant Proc 1972; 4(4): 487.
10. Monaco AP, Wood ML, Gray JG, Russell PS. Studies on heterologous anti-lymphocyte serum in mice. II. Effect on the immune response. J Immunol 1966; 96(2): 229.
11. Gray JG, Monaco AP, Wood ML, Russell PS. Studies on heterologous anti-lymphocyte serum in mice. I. In vitro and in vivo properties. J Immunol 1966; 96(2): 217.
12. Robertson AM, Bird CC, Waddell AW, Currie AR. Morphological aspects of glucocorticoid-induced cell death in human lymphoblastoid cells. J Pathol 1978; 126(3): 181.
13. Warner TF. Apoptosis. Lancet 1972; 2(7789): 1252.
14. Greco B, Bielory L, Stephany D, et al. Antithymocyte globulin reacts with many normal human cell types. Blood 1983; 62(5): 1047.
15. Bonnefoy-Berard N, Genestier L, Flacher M, et al. Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. Blood 1994; 83(4): 1051.
16. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991; 51(3): 669.
17. Raefsky EL, Gascon P, Gratwohl A, et al. Biological and immunological characterization of ATG and ALG. Blood 1986; 68(3): 712.
18. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79(11): 1507.
19. Zand MS, Vo T, Pellegrin T, et al. Apoptosis and complement mediated lysis of myeloma cells by polyclonal rabbit anti-thymocyte globulin. Blood 2006; 107: 2895-2903.
20. Ayuk FA, Fang L, Fehse B, et al. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol 2005; 33(12): 1531.
21. Bonnefoy-Berard N, Flacher M, Revillard JP. Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. Blood 1992; 79(8): 2164.
22. Fassbinder W, Scheuermann EH, Stutte HJ, et al. Improved graft prognosis by treatment of steroid resistant rejections with ATG and plasmapheresis. Proc Eur Dial Transplant Assoc 1983; 20: 362.
23. Richardson AJ, Higgins RM, Liddington M, et al. Antithymocyte globulin for steroid resistant rejection in renal transplant recipients immunosuppressed with triple therapy. Transpl Int 1989; 2(1): 27.
24. Cantarovich M, Latter DA, Loertscher R. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Clin Transplant 1997; 11(4): 316.
25. Shah A, Nadasdy T, Arend L, et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004; 77(9): 1399.
26. Hofmann WJ, Momburg F, Moller P. Thymic medullary cells expressing B lymphocyte antigens. Hum Pathol 1988; 19(11): 1280.
27. Hofmann WJ, Momburg F, Moller P, Otto HF. Intra- and extrathymic B cells in physiologic and pathologic conditions. Immunohistochemical study on normal thymus and lymphofollicular hyperplasia of the thymus. Virchows Arch A Pathol Anat Histopathol 1988; 412(5): 431.
28. Isaacson PG, Norton AJ, Addis BJ. The human thymus contains a novel population of B lymphocytes. Lancet 1987; 2(8574): 1488.
29. Schlesinger M. Antigens of the thymus. Prog Allergy 1972; 16: 214.
30. Tonnelle C, D'Ercole C, Depraetere V, et al. Human thymic B cells largely overexpress the VH4 Ig gene family. A possible role in the control of tolerance in situ? Int Immunol 1997; 9(3): 407.
31. Seiler FR. Development, production and quality control of clinically applied antilymphocyte globulin. Postgrad Med J 1976; 52 (5 Suppl): II.
32. Christensson B, Biberfeld P, Matell G. B-cell compartment in the thymus of patients with myasthenia gravis and control subjects. Ann N Y Acad Sci 1988; 540: 293.
33. Fend F, Nachbaur D, Oberwasserlechner F, et al. Phenotype and topography of human thymic B cells. An immunohistologic study. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 60(6): 381.
34. Pugh-Bernard AE, Silverman GJ, Cappione AJ, et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 2001; 108(7): 1061.
35. Cappione AJ, Pugh-Bernard AE, Anolik JH, Sanz I. Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. J Immunol 2004; 172(7): 4298.
36. Fang L, Fehse B, Engel M, et al. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005; 79(3): 369.
37. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59(8): 1194.
38. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66(1): 29.
39. Juliusson G, Theorin N, Karlsson K, et al. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006; 7(5): 503-510.
40. Muller TF, Grebe SO, Neumann MC, et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997; 64(10): 1432.
41. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71(3): 460.
42. Neumann MC, Muller TF, Sprenger H, et al. The influence of the immunosuppressants OKT3 and ATG on immunological parameters. Clin Nephrol 1996; 45(5): 345.
43. Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91(7): 2360.
44. Michallet MC, Saltel F, Preville X, et al. Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood 2003; 102(10): 3719.
45. Bains SK, Mone A, Yun Tso J, et al. Mitochondria control of cell death induced by anti-HLA-DR antibodies. Leukemia 2003; 17(7): 1357.
46. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275.
47. Thibeault A, Zekki H, Mourad W, et al. Triggering HLA-DR molecules on human peripheral monocytes induces their death. Cell Immunol 1999; 192(1): 79.
48. Drenou B, Blancheteau V, Burgess DH, et al. A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes. J Immunol 1999; 163(8): 4115.
49. Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 2002; 8(8): 801.
50. Blancheteau V, Charron D, Mooney N. HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases. Hum Immunol 2002; 63(5): 375.
51. Lee JW, Gersuk GM, Kiener PA, et al. HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand. J Immunol 1997; 159(7): 3211.
52. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000; 26(2): 133.
53. Kim D, Hur DY, Kim YS, et al. CM1 ligation initiates apoptosis in a caspase 8-dependent manner in Ramos cells and in a mitochondria-controlled manner in Raji cells. Hum Immunol 2002; 63(7): 576.
54. Schroder C, Azimzadeh AM, Wu G, et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003; 12(1): 19.
55. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004; 83(10): 634.
56. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95(12): 3900.
57. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48(2): 455.
58. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50(11): 3580.
59. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 1997; 17(3): 1535.
60. Harlin H, Podack E, Boothby M, Alegre ML. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J Immunol 2002; 169(5): 2451.
61. Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102(3): 1019.
62. Cerutti A, Schaffer A, Goodwin RG, et al. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. J Immunol 2000; 165(2): 786.
63. Levi E, Pfeifer WM, Kadin ME. CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest? Blood 2001; 98(5): 1630.
64. Berro AI, Perry GA, Agrawal DK. Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol 2004; 173(3): 2174.
65. Atrah HI, Sandilands GP. A proposed mechanism of action for ALG and ATG in severe acquired aplastic anaemia. J Clin Lab Immunol 1988; 25(2): 59.
66. Amemiya H, Yokoyama T, Putnam CW, et al. The nature of antiplatelet activity in antilymphoblast ALG-with special reference to cross-reacting antibody, immunochemical characterization, and Coombs' positive thrombocytopenia in ALG-treated renal recipients. Clin Exp Immunol 1972; 10(3): 417.
67. Ankersmit HJ, Roth GA, Moser B, et al. CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin: implication of therapy-induced in vivo thrombocytopenia. Am J Transplant 2003; 3(6): 754.
68. Binstadt BA, Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003; 111(4): 697.
69. Antonsson A, Johansson PJ. Binding of human and animal immunoglobulins to the IgG Fc receptor induced by human cytomegalovirus. J Gen Virol 2001; 82 (Pt 5): 1137.
70. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13(12): 1551.
71. Amigorena S, Bonnerot C, Drake JR, et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 1992; 256(5065): 1808.
72. Choquet D, Partiseti M, Amigorena S, et al. Cross-linking of IgG receptors inhibits membrane immunoglobulin-stimulated calcium influx in B lymphocytes. J Cell Biol 1993; 121(2): 355.
73. Mathiot C, Amigorena S, Moncuit J, et al. In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc gamma RII+ T cell hybridoma and by immunoglobulin G-binding factors. Immunol Res 11 (3- 4):296, 1992.
74. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998; 160(1): 395.
75. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r) evolutionary story of enzymes and receptors. Leuk Res 2001; 25(1): 1.
76. Kumagai M, Coustan-Smith E, Murray DJ, et al. Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med 1995; 181(3): 1101.
77. Silvennoinen O, Nishigaki H, Kitanaka A, et al. CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C-gamma and phosphatidylinositol 3-kinase. J Immunol 1996; 156(1): 100.
78. Tenca C, Merlo A, Zarcone D, et al. Death of T cell precursors in the human thymus: a role for CD38. Int Immunol 2003; 15(9): 1105.
79. Funaro A, Morra M, Calosso L, et al. Role of the human CD38 molecule in B cell activation and proliferation. Tissue Antigens 1997; 49(1): 7.
80. Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999; 94(2): 701.
81. Kawano MM, Mihara K, Huang N, et al. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995; 85(2): 487.
82. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001; 97(6): 1817.
83. Hirata T, Shimazaki C, Sumikuma T, et al. Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro. Leuk Res 2003; 27(4): 343.
84. Preville X, Nicolas L, Flacher M, Revillard J. A quantitative flow cytometry assay for the preclinical testing and pharmacological monitoring of rabbit antilymphocyte globulins (rATG). J Immunol Methods 245 (1-2):45, 2000.
85. Zand MS, Vo T, Pellegrin T, et al. Apoptosis and complement mediated lysis of myeloma cells by polyclonal rabbit anti-thymocyte globulin. Blood 2006; 107: 2895.
86. Knight KL, Burnett RC, McNicholas JM. Organization and polymorphism of rabbit immunoglobulin heavy chain genes. J Immunol 1985; 134(2): 1245.
87. Wagner B. Immunoglobulins and immunoglobulin genes of the horse. Dev Comp Immunol 30 (1-2):155, 2006.
88. Banks KL, McGuire TC. Surface receptors on neutrophils and monocytes from immunodeficient and normal horses. Immunology 1975; 28(3): 581.
89. Tschetter JR, Byrne KM, Perryman LE, McGuire TC. Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies. Virology 1997; 230(2): 275.
90. Pescovitz MD, Book BK, Milgrom ML, et al. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts. Surgery 1994; 116(4): 811.
91. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3(6): 708.
92. Furth S, Neu AM, Hart J, et al. Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Pediatr Transplant 1999; 3(2): 146.
93. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66(6): 800.
94. Jordan SC, Vo AA, Toyoda M, et al. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transplant 2005; 9(2): 155.
95. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70(6): 887.
96. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4(6): 996.
97. Garrett HE, Jr., Groshart K, Duvall-Seaman D, et al. Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002; 74(4): 1240.
98. Jordan SC, Vo AA, Tyan D, et al. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005; 9(3): 408.
99. Tinckam KJ, Wood IG, Ji F, Milford EL. ATG induction is associated with an increase in anti-HLA antibodies after kidney transplantation. Hum Immunol 2004; 65(11): 1281.
100. Colovai AI, Vasilescu ER, Foca-Rodi A, et al. Acute and hyperacute humoral rejection in kidney allograft recipients treated with antihuman thymocyte antibodies. Hum Immunol 2005; 66(5): 501.
101. Kaden J, May G, Schonemann C, et al. Effect of ATG prophylaxis in sensitized and non-sensitized kidney graft recipients. Transpl Int 1992; 5 Suppl 1: S75.
102. Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005; 35(10): 1011.
103. Schnetzler B, Leger P, Volp A, et al. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients. Transpl Int 2002; 15(6): 317.
104. Remberger M, Aschan J, Barkholt L, et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001; 15(3): 147.
105. Bacigalupo A, Oneto R, Lamparelli T, et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 2001; 28(12): 1093.
106. Bock P, Hobler N, Caudrelier P, Alberici G. Treatment of acute rejection in renal graft recipients by thymoglobuline: a retrospective multicenter analysis. Transplant Proc 1995; 27(1): 1058.
107. Bock HA, Gallati H, Zurcher RM, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation 1995; 59(6): 830.
108. Samsel R, Chmura A, Wlodarczyk Z, et al. Perioperative single high dose ATG-Fresenius S administration as induction immunosuppressive therapy in cadaveric renal transplantation-preliminary results. Ann Transplant 1999; 4(2): 37.
109. Zander AR, Kroger N, Schleuning M, et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003; 32(4): 355.
110. Diethelm AG, Aldrete JS, Shaw JF, et al. Clinical evaluation of equine antithymocyte globulin in recipients of renal allografts: Analysis of survival, renal function, rejection, histocompatibility, and complications. Ann Surg 1974; 180(1): 20.
111. Satoh P, Elberg A, Davis J, et al. Effects of different ATG (ATGAM) regimens on levels of rosette-forming cells (RFC), serum horse IgG (HoI), and anti-horse antibodies in kidney transplant patients. Transplant Proc 1979; 11(2): 1427.
112. Sansom JR, Barnes AD, Hall CL. A randomized prospective clinical trial of antilymphocyte globulin in 100 cadaveric renal transplants. Postgrad Med J 1976; 52 (5 Suppl): 75.
113. Wechter WJ, Morrell RM, Bergan J, et al. Extended treatment with antithymocyte globulin (ATGAM) in renal allograft recipients. Transplantation 1979; 28(5): 365.
114. Wechter WJ, Brodie JA, Morrell RM, et al. Antithymocyte globulin (ATGAM) in renal allograft recipients. Multicenter trials using a 14-dose regimen. Transplantation 1979; 28(4): 294.
115. Paquette RL, Tebyani N, Frane M, et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood 1995; 85(1): 283.
116. Indudhara R, Novick AC, Hodge E, et al. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin. Urology 1996; 47(6): 807.
117. Birkeland SA. A controlled clinical trial of treatment with ALG in established rejection of renal allografts. Acta Med Scand 1975; 198(6): 489.
118. Howard RJ, Condie RM, Sutherland DE, et al. The use of antilymphoblast globulin in the treatment of renal allograft rejection: a double-blind, randomized study. Transplantation 1977; 24(6): 419.
119. Howard RJ, Condie RM, Sutherland DE, et al. The effect of serum ALG concentrations on results following renal transplantation. Ann Surg 1977; 186(5): 619.
120. Najarian JS, Simmons RL, Condie RM, et al. Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg 1976; 184(3): 352.